Rubicon Research Ltd
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.[1]
- Market Cap ₹ 10,752 Cr.
- Current Price ₹ 653
- High / Low ₹ 672 / 571
- Stock P/E 80.0
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 28.6 %
- ROE 34.9 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 23.0% CAGR over last 5 years
- Debtor days have improved from 141 to 85.7 days.
- Company's working capital requirements have reduced from 56.5 days to 37.6 days
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 263 | 315 | 314 | 394 | 854 | 1,284 | |
| 182 | 223 | 353 | 375 | 699 | 1,028 | |
| Operating Profit | 81 | 92 | -39 | 18 | 155 | 256 |
| OPM % | 31% | 29% | -12% | 5% | 18% | 20% |
| 18 | 10 | 17 | 25 | 18 | 12 | |
| Interest | 6 | 9 | 10 | 19 | 31 | 37 |
| Depreciation | 18 | 29 | 34 | 36 | 39 | 37 |
| Profit before tax | 74 | 63 | -66 | -11 | 103 | 195 |
| Tax % | 33% | 51% | 2% | 53% | 12% | 31% |
| 49 | 31 | -67 | -17 | 91 | 134 | |
| EPS in Rs | 97.46 | 60.53 | -132.39 | -33.31 | 5.98 | 8.72 |
| Dividend Payout % | 2% | 2% | -0% | -2% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 37% |
| 3 Years: | 60% |
| TTM: | 50% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 59% |
| TTM: | 48% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 21% |
| Last Year: | 35% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 15 | |
| Reserves | 335 | 369 | 300 | 281 | 370 | |
| 30 | 93 | 175 | 320 | 425 | ||
| 60 | 71 | 79 | 144 | 300 | ||
| Total Liabilities | 430 | 538 | 560 | 750 | 1,109 | |
| 157 | 188 | 193 | 199 | 307 | ||
| CWIP | 2 | 6 | 3 | 25 | 10 | |
| Investments | 19 | 14 | 0 | 0 | 0 | |
| 252 | 330 | 364 | 526 | 793 | ||
| Total Assets | 430 | 538 | 560 | 750 | 1,109 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 5 | 62 | -63 | -75 | 21 | 159 | |
| -84 | -46 | -46 | -32 | -68 | -65 | |
| 80 | 52 | 63 | 123 | 44 | -40 | |
| Net Cash Flow | 1 | 67 | -45 | 16 | -4 | 55 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 194 | 158 | 162 | 209 | 129 | |
| Inventory Days | 360 | 508 | 502 | 609 | 421 | |
| Days Payable | 183 | 271 | 320 | 353 | 247 | |
| Cash Conversion Cycle | 371 | 395 | 345 | 465 | 302 | |
| Working Capital Days | 183 | 149 | 107 | 75 | 57 | |
| ROCE % | 17% | -12% | 1% | 19% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Acquisition
28 Oct - Rubicon to acquire up to ~10.5% of Neuronasal for up to USD 2.5M via milestones by March 31, 2027.
-
Announcement under Regulation 30 (LODR)-Acquisition
21 Oct - Advagen to acquire Gen1E preferred stock up to USD3M; $2M by Mar31,2026; $1M via milestones to Dec31,2027.
- Closure of Trading Window 17 Oct
- Listing of Equity Shares of Rubicon Research Ltd 16 Oct
Business Profile[1]
Rubicon Research Limited is a formulation-focused pharmaceutical company focusing predominantly on the United States. The company has established a strong presence in the US generic and specialty drug market, which contributed 99.5% of its revenue in Q1 FY26.